Mereo BioPharma (MREO) Enterprise Value (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Enterprise Value of -$36.2 million for Q1 2026, up 42.04% year-over-year from -$25.5 million in Q1 2025, and up 11.63% quarter-over-quarter from -$41.0 million in Q4 2025.
Mereo BioPharma (MREO) Enterprise Value (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Enterprise Value for 10 consecutive years, with -$36.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 42.04% year-over-year to -$36.2 million; the TTM figure through Mar 2026 stood at -$36.2 million (up 42.04% YoY), while the FY2025 annual figure was -$41.0 million, up 41.27% from the prior year.
- Enterprise Value advanced to -$36.2 million in Q1 2026 per MREO's latest filing, from -$41.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$36.2 million in Q1 2026 and bottomed at -$96.2 million in Q2 2022.
- Historically, Enterprise Value has averaged -$61.8 million across 5 years, with a median of -$57.4 million in 2023.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 48.02% — and 2024, when it plunged 65.91%.
- Mereo BioPharma's Enterprise Value stood at -$66.1 million in 2022, then rose by 13.1% to -$57.4 million in 2023, then fell by 21.56% to -$69.8 million in 2024, then surged by 41.27% to -$41.0 million in 2025, then climbed by 11.63% to -$36.2 million in 2026.
- Business Quant data shows MREO's Enterprise Value at -$36.2 million in Q1 2026, -$41.0 million in Q4 2025, and -$48.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Mereo BioPharma | 47.15 Mn | 47.15 Mn | - | -30.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.12 Mn |
| Mar 31, 2026 | -36.22 Mn |
| Dec 31, 2025 | -40.99 Mn |
| Sep 30, 2025 | -48.70 Mn |
| Jun 30, 2025 | -56.13 Mn |
| Mar 31, 2025 | -62.50 Mn |
| Dec 31, 2024 | -69.80 Mn |
| Sep 30, 2024 | -80.52 Mn |
| Jun 30, 2024 | -87.43 Mn |
| Mar 31, 2024 | -48.70 Mn |
| Dec 31, 2023 | -57.42 Mn |
| Jun 30, 2023 | -52.70 Mn |
| Dec 31, 2022 | -66.08 Mn |
| Jun 30, 2022 | -96.23 Mn |
| Dec 31, 2021 | -127.11 Mn |
| Jun 30, 2021 | -153.88 Mn |
| Dec 31, 2020 | -30.99 Mn |
| Jun 30, 2020 | -70.55 Mn |
| Dec 31, 2019 | -21.02 Mn |
| Jun 30, 2019 | -46.46 Mn |